All Neurosciences articles
-
NewsKCL-286 targets multiple Alzheimer’s pathways in preclinical study
A repurposed small molecule originally developed for spinal cord injury has demonstrated the ability to address multiple disease-relevant pathways in Alzheimer’s disease, including DNA damage and neuroinflammation, offering a potential route to disease-modifying therapy.
-
News15-PGDH enzyme inhibition protects brain cells in Parkinson’s disease models
Researchers have identified 15-PGDH enzyme inhibition as a neuroprotective strategy in Parkinson’s disease, with repurposable compounds already in clinical development offering a potential shortcut to disease-modifying therapies.
-
Newsbit.bio launches iPSC-derived cell culture media kits to democratise human cell research
Cambridge-based cell programming company bit.bio has introduced two new media kits for its iPSC-derived ioGlutamatergic Neurons and ioMicroglia, reducing media preparation costs by around 18-fold and simplifying workflows to widen access to human-relevant research models.
-
NewsCerebral organoids identify Ebola virus persistence in neural tissue
Researchers have used human brain organoids to demonstrate that Ebola virus can replicate in neural tissue for up to 120 days, offering new insights into viral persistence mechanisms in immune-privileged sites and late-stage inflammatory complications in survivors.
-
ArticleCerebral organoids reveal how Ebola virus persists in neural tissue
How does Ebola virus survive long after recovery? A new study using human cerebral organoids explores viral persistence in neural tissue and the growing role of organoid models in drug discovery research.
-
NewsNew framework standardises glioma organoid research for translational studies
A collaborative review published in Neuro-Oncology establishes a unified classification system for glioma organoid models, addressing inconsistent terminology and methodology across the rapidly expanding field.
-
NewsAI-powered $6M project targets new Alzheimer’s treatments
A $6 million NIH-funded collaboration between Indiana University School of Medicine and Luddy School of Informatics aims to deploy AI and machine learning to identify promising Alzheimer’s drug candidates, screening billions of compounds to overcome traditional discovery bottlenecks.
-
NewsGlycine transporter suppression restores NMDAR function in autism models
Researchers have identified a novel therapeutic strategy for autism spectrum disorder by suppressing the glycine transporter SLC6A20, successfully restoring NMDA receptor function in both mouse models and human cortical organoids carrying SHANK2 and SHANK3 mutations.
-
NewsOrganoid study reveals valproate’s impact on developing brain
German researchers have used cerebral organoids to investigate how the epilepsy medication valproate interferes with early brain development, identifying significant disruption to the extracellular matrix and neuronal maturation that may explain increased neurodevelopmental risks in exposed foetuses.
-
ArticleBeyond tangles: why soluble intracellular tau should guide drug discovery
Tau tangles are a hallmark of Alzheimer’s disease and related disorders, but evidence suggests the real damage may come from rare, soluble tau species inside neurons. Targeting these hidden drivers of circuit dysfunction could be key to restoring memory and cognition.
-
NewsStudy reveals how GLP-1 drugs trigger weight loss in brain cells
NIH researchers have identified the intracellular signalling pathways through which semaglutide and other GLP-1 receptor agonists induce weight loss, revealing why patient responses vary and treatment effects plateau over time.
-
NewsAI-designed viral vectors achieve 50-fold brain enrichment over AAV9
WhiteLab Genomics has presented preclinical data showing that viral vectors designed using artificial intelligence achieved approximately 50-fold higher DNA enrichment in the brain compared to AAV9, with no detectable liver signal following intravenous administration in mice.
-
NewsMachine learning identifies five distinct Parkinson’s disease subtypes
A new study from VIB and KU Leuven has revealed that Parkinson’s disease comprises five distinct molecular subtypes, each requiring tailored therapeutic approaches.
-
NewsNasal spray reverses age-related brain inflammation in preclinical study
Researchers at Texas A&M University have developed a nasal spray delivering extracellular vesicles that reverses neuroinflammaging in preclinical models. Two doses significantly reduced brain inflammation, restored mitochondrial function and improved memory within weeks, with effects persisting for months. The therapy bypasses the blood-brain barrier and targets inflammatory pathways whilst reactivating cellular energy production.
-
NewsFGF21 hormone targets hindbrain pathways to reverse obesity
New research reveals that FGF21, a hormone under investigation for obesity and metabolic dysfunction-associated steatohepatitis (MASH), works by signalling to the hindbrain rather than the hypothalamus. The discovery of this distinct neural circuit—which increases metabolic rate rather than simply suppressing appetite—could enable development of more precise therapies with fewer adverse effects than current FGF21 analogues.
-
NewsSmall molecule SK-129 targets protein aggregation in Parkinson’s disease
International researchers have identified a small molecule capable of crossing the blood-brain barrier to prevent pathological protein aggregation in Parkinson’s disease, Lewy body dementia and multiple system atrophy.
-
NewsScientists scale up neural organoid studies for drug testing
Researchers at King’s College London have developed a hybrid neural organoid approach that addresses longstanding limitations in scalability, reproducibility and longitudinal analysis. By dissociating 3D organoids and culturing pooled cells on microelectrode arrays, the team created 2D networks that retain cellular diversity whilst enabling consistent, long-term tracking of neural activity across parallel cultures.
-
WebinarWhat it takes to automate high-content imaging at scale
This webinar examines the design trade-offs and technical constraints involved in building a high-throughput robotic imaging pipeline for complex biological workflows.
-
ArticleWhy NMDA receptor modulation remains central to next-generation depression therapies
A key player in brain communication and mood regulation, the pharmaceutical industry views the NMDAR as the central pillar for next-generation therapies for depression. Dirk Beher from FundaMental Pharma reveals new strategies for targeting this important receptor.
-
NewsPsychedelics may repair brain myelin to aid PTSD recovery
Psychedelic drugs such as psilocybin and MDMA may help repair the brain’s insulating myelin layer, according to new research.